Evidence map›Paper›PMID 20720033›Full record

ArticleJournal of clinical microbiology2010

Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings.

Padmapriya P Banada, Satheesh K Sivasubramani, Robert Blakemore, Catharina Boehme, Mark D Perkins, Kevin Fennelly, David Alland

Registry-linked trialAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02776150 (Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis), which is not on this map. Cited by 74 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02776150 unknown statusnot on this mapstarted 2016, after this paper: background citation

Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis

TypeobservationalSponsorBeijing HospitalRan2016 to 2019Enrolled3,100ConditionsTuberculosis, Pulmonary
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019
    Pooled it
  10. XpertThe Cochrane database of systematic reviews · 2018
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Padmapriya P BanadaNew Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.
Satheesh K Sivasubramani
Robert Blakemore
Catharina Boehme
Mark D Perkins
Kevin Fennelly
David Alland

Funding

Sample Processing Cartridges for Rapid PCR TB DetectionR42AI052523 · NIAID · CEPHEID · PI ALLAND, DAVID · 2006 to 2008
$4.0M
Sample Processing Cartridges for Rapid PCR TB DetectionR41AI052523 · NIAID · CEPHEID · PI ALLAND, DAVID · 2002 to 2002
$376k
NIAID NIH HHS R41 AI052523NIAID NIH HHS R41-AI52523NIAID NIH HHS R42 AI052523NIAID NIH HHS R42-AI52523
6 · The paper itself

Abstract

The recently introduced Xpert MTB/RIF assay (Xpert) has point-of-care potential, but its capacity for biohazard containment remained to be studied. We compared the bioaerosols generated by the Xpert assay to acid-fast bacillus (AFB) microscope slide smear preparation. The Xpert assay sample treatment reagent (SR) was also studied for its sterilizing capacity, stability, and effect on assay sensitivity after prolonged treatment. During the preparation of AFB smears, sputum samples spiked with Mycobacterium bovis BCG at 5 × 10(8) CFU/ml produced 16 and 325 CFU/m(3) air measured with an Andersen impactor or BioSampler, respectively. In contrast, neither the sample preparation steps for the Xpert assay nor its automated processing produced any culturable bioaerosols. In testing of SR sterilizing capacity, clinical sputum samples from strongly smear-positive tuberculosis patients treated with SR at a 2:1 ratio eliminated Mycobacterium tuberculosis growth in all but 1/39 or 3/45 samples cultured on solid or liquid medium, respectively. These few unsterilized samples had a mean 13.1-day delay in the time to positive culture. SR treatment at a 3:1 ratio eliminated growth in all samples. SR retained a greater than 6-log-unit killing capacity despite storage at temperatures spanning 4 to 45°C for at least 3 months. The effect of prolonged SR sample treatment was also studied. Spiked sputum samples could be incubated in SR for up to 3 days without affecting Xpert sensitivity for M. tuberculosis detection and up to 8 h without affecting specificity for rifampin resistance detection. These results suggest that benchtop use of the Xpert MTB/RIF assay limits infection risk to the user.

Indexed as

Point-of-Care SystemsAerosolsAir MicrobiologyAntitubercular AgentsBacteriological TechniquesContainment of BiohazardsDrug Resistance, BacterialHumansMycobacterium bovisMycobacterium tuberculosisRifampinSensitivity and SpecificitySputumSterilizationTuberculosisAerosolsAntitubercular AgentsRifampin

Identifiers

PMID20720033
PMCPMC2953088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.